GLIA Diagnostics
Australian medical-technology company developing an investigational point-of-care molecular diagnostic platform to provide objective biological information after traumatic brain injury (TBI). The programme is based on a clinically studied multiplex circulating microRNA panel and is being translated toward a portable cartridge-and-reader system intended for finger‑stick whole blood with a target ~20-minute sample-to-result workflow. Clinical, analytical and regulatory validation remain ongoing; the platform is investigational and not approved for clinical use.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Portable point-of-care miRNA diagnostic platform (single-use cartridge + compact reader)
Investigational near-patient system intended to quantify a multi-marker circulating microRNA panel from a small-volume whole-blood sample (finger-stick or venepuncture) using a single-use cartridge and compact reader.
GLIA Point-of-Care TBI Platform
A portable point-of-care platform combining a biological sample, cartridge, and handheld reader to provide objective biological information following traumatic brain injury and concussion.
Portable point-of-care miRNA diagnostic platform (single-use cartridge + compact reader)
Investigational near-patient system intended to quantify a multi-marker circulating microRNA panel from a small-volume whole-blood sample (finger-stick or venepuncture) using a single-use cartridge and compact reader.
GLIA Point-of-Care TBI Platform
A portable point-of-care platform combining a biological sample, cartridge, and handheld reader to provide objective biological information following traumatic brain injury and concussion.
Services
Collaborative planning and execution of human clinical cohorts, longitudinal sampling and analytical validation studies to evaluate biomarker performance in sport, military and civilian populations.
Technical collaboration for cartridge integration, reader hardware and software development, and field-deployment prototyping.
Collaborative planning and execution of human clinical cohorts, longitudinal sampling and analytical validation studies to evaluate biomarker performance in sport, military and civilian populations.
Technical collaboration for cartridge integration, reader hardware and software development, and field-deployment prototyping.
Expertise Areas
- Point-of-care molecular diagnostics
- Clinical trial design and cohort management (prospective, longitudinal)
- Biomarker discovery and multi-marker panel development (miRNA)
- Translational assay development (cartridge and reader integration)
Key Technologies
- Circulating microRNA biomarker panels
- Point-of-care cartridge-and-reader diagnostic platforms
- Microfluidic diagnostic cartridges
- Finger-stick whole blood assay workflows
News & Updates
Pilot study identifying candidate circulating microRNAs with potential utility for diagnosis and prognosis following TBI.
Longitudinal cohort study examining relationships between circulating microRNA levels and symptom trajectories following mild TBI.
Prospective cohort evaluation of microRNA biomarkers for diagnosis of mTBI and prediction of persistent post-concussive symptoms.
Prospective cohort study assessing day-of-injury microRNA levels among patients who developed post-concussive symptoms at 28 days.
Pilot study identifying candidate circulating microRNAs with potential utility for diagnosis and prognosis following TBI.
Longitudinal cohort study examining relationships between circulating microRNA levels and symptom trajectories following mild TBI.
Prospective cohort evaluation of microRNA biomarkers for diagnosis of mTBI and prediction of persistent post-concussive symptoms.
Prospective cohort study assessing day-of-injury microRNA levels among patients who developed post-concussive symptoms at 28 days.